High-Throughput Ribozyme-Based Assays for Detection of Viral Nucleic Acids  by Kossen, Karl et al.
Chemistry & Biology, Vol. 11, 807–815, June, 2004, 2004 Elsevier Ltd. All rights reserved. DOI 10.1016/j .chembiol .2004.03.029
High-Throughput Ribozyme-Based Assays
for Detection of Viral Nucleic Acids
gesting that this approach for nucleic acid detection is
generally applicable [1].
Half-ribozymes are considerably more sensitive than
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creased rate differential between target-activated catal-
ysis and background ligation (2.6  109-fold; [1]) rela-Summary
tive to other ribozyme-based detection systems (1 
104-fold; [6]) translates directly into the increased sensi-Many reports have suggested that target-activated ri-
tivity provided by half-ribozymes. Indeed, this rate differ-bozymes hold potential value as detection reagents.
ential was used to predict the sensitivity of detectionWe show that a “half”-ribozyme ligase is activated
that was demonstrated in an assay employing detectionsimilarly by three unstructured oligoribonucleotides
of radiolabeled product RNA [1].representing the major sequence variants of a hepati-
In the present work, we investigated whether thistis C virus 5-untranslated region (5-UTR) target and
HCV-activated half-ribozyme is capable of detectingby a structured RNA corresponding to the entire 5-
natural sequence variants of its target, whether func-UTR. Half-ribozyme ligation product was detected
tional target can be readily derived from a large, struc-both in an ELISA-like assay and in an optical immuno-
tured RNA, and whether half-ribozymes are compatibleassay through the use of hapten-carrying substrate
with immunodiagnostic detection platforms.RNAs. Both assay formats afford a limit of detection
of approximately 1  106 HCV molecules (1.6 attomol,
330 fM), a sensitivity which compares favorably to that
Results and Discussionprovided by standard immunoassays. These data sug-
gest that target-activated ribozyme systems are a via-
The half-ribozyme previously developed is activated byble approach for the sensitive detection of viral nucleic
a conserved sequence in the 5-untranslated region (5-acids using high-throughput platforms.
UTR) of the hepatitis C virus [1]. Although this target
represents one of the most highly conserved portions
Introduction of the HCV genome, it is not universally conserved in
reported HCV sequences. Therefore, we investigated
Applications ranging from basic research to molecular whether naturally occurring variants of the HCV target
diagnostics require the sensitive detection of nucleic could activate half-ribozyme catalysis in order to estab-
acids. We recently described a new class of target- lish whether the HCV sequence-activated half-ribozyme
activated ribozymes, which we termed “half”-ribozymes could act as a general HCV-detection reagent.
[1], that are based on 3-truncated class I ligases [2–5]. Since 1431 sequences corresponding to the 5-UTR
Half-ribozymes are active only when bound to a specific of HCV are deposited in GenBank, the variation of this
trans-acting nucleic acid that supplies the deleted se- sequence can be robustly investigated. Remarkably,
quence, allowing the ligation of two substrate RNAs to only three different target sequences represent80% of
be used as a readout for the presence of a target nucleic all GenBank entries of the 5-UTR [1]. The most prevalent
acid. The catalytic nature of half-ribozymes allows for sequence, which is found in 66.3% of GenBank entries,
a single molecular recognition event to facilitate multiple was used to initially generate the HCV-activated half-
RNA-ligation reactions and therefore provides a signal ribozyme (target 1 in green, Figure 1A). The second most
amplification step for target detection. Iterative RNA prevalent sequence, which represents 8.3% of GenBank
selection techniques can be used to develop half-ribo- entries, changes an A-U base pair at position 15 to a
zymes activated by different target sequences, sug- noncanonical G-U base pair, replaces a C-G base pair
at position 19 with an A/G internal bulge, and replaces
*Correspondence: sseiwert@intermune.com (S.D.S.), poliskyb@ an internal C/A bulge at position 23 with an U-A base pair
sirna.com (B.P.) (target 2, Figure 1A). The next most prevalent sequence
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Figure 1. A Half-Ribozyme Activated by Natural Sequence Variants of HCV
(A) Half-ribozyme (black) interacts with a conserved sequence of the HCV genome (green). A SOH/pppS bimolecular substrate RNA complex
(red and blue, respectively) interacts with the half-ribozyme-HCV target complex by forming base pairs with the HCV target. The target-
activated half-ribozyme catalyzes the ligation of SOH and pppS by directing nucleophilic attack of the 3-cis-diol of SOH on the -phosphate of
pppS (arrow). Circled nucleotides in the target are sites of changes in the second and third most common variations of this sequence, targets
2 and 3, respectively. Relative to the consensus sequence, target 2 carries three changes at positions 15, 19, and 21, and target 3 contains
a single C to U transition at position 19.
(B) Half-ribozyme catalysis with natural variants of the HCV target. Multiple turnover ligation rates were measured in the presence of a trace
concentration of targets 1–3 and increasing concentrations of half-ribozyme. Rates with targets 1–3 and an unrelated target RNA of a different
half-ribozyme are shown as green squares, orange triangles, orange diamonds, and black circles, respectively. The concentration of half-
ribozyme was varied between 1 and 320 nM as shown, and the SOH and pppS RNAs were present at 10 M.
We assessed the ability of each of these three HCV ribozyme concentration used in assays to detect trace
target, the amount of product formed in response totargets to activate half-ribozyme catalysis. Since these
three targets are expected to have differing affinities for each target will be determined by the maximal rate it
affords the half-ribozyme. The maximal rates affordedthe half-ribozyme, the target binding region of the half-
ribozyme was extended by 13 nucleotides relative to by target 1 and target 3 were similar (10.0 min1 versus
9.1 min1, respectively), but target 2 elicited a 30%the half-ribozyme described previously [1] in order to
maximize capture of all targets at the lowest possible lower rate (7.0 min1). This result suggests that the HCV
half-ribozyme will have a similar ability to detect eachhalf-ribozyme concentration (Figure 1A). (Note: this ex-
tension does not alter the kinetic performance of the of the three targets. Thus, in so far as the 1431 entries
in GenBank reflect the natural variation of the target inHCV half-ribozyme; data not shown). For each target, the
maximal half-ribozyme rate (kmax) and apparent binding HCV 5-UTR, the half-ribozyme can serve as a detection
reagent for 80%, and possibly more, of reported HCVconstant (Kapp) were determined by monitoring the liga-
tion rate as a function of half-ribozyme concentration in strains.
In contrast to the very similar kinetic performance ofthe presence of a trace amount of target (Figure 1B).
The apparent binding constant for each of the HCV- targets 1–3, a non-HCV RNA that serves to activate a
distinct half-ribozyme [1] failed to activate catalysis oftarget variants was less than or equal to 4 nM (Figure
1B). This result suggests that the half-ribozyme has a the HCV-activated half-ribozyme at any half-ribozyme
concentration tested (Figure 1B and data not shown).similar affinity for each target sequence, and that each
sequence will be quantitatively bound in experiments The specificity of the HCV-activated half-ribozyme em-
phasizes that, like other target-activated ribozymes [13,used to detect and quantify HCV nucleic acid, which
are performed at 1 M half-ribozyme. Moreover, the 14], half-ribozyme activity relies on the ability of the
target both to bind and to orient active site residues forvery low apparent binding constants suggest that the
half-ribozyme may be able to bind more divergent HCV- catalysis. While it is unlikely that the non-HCV sequence
in Figure 1B does either, the lower kmax observed withtarget sequences in these assays.
Since all of the target sequences have similar appar- target 2 may reflect a perturbation in the structure of the
target-half-ribozyme complex. Of the three nucleotideent binding constants, which are well below the half-
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Figure 2. Half-Ribozyme Activation by Structured RNAs
(A) HCV 5-UTR. DNA oligonucleotides (gray) used to direct RNase cleavage of the 5-UTR are complementary to the sequences that flank
the location of the HCV target (outline).
(B) Cleavage of radiolabeled 5-UTR. Lanes 1 and 7, RNA markers; lanes 2–6, 5-UTR treated as indicated; lane 8, synthetic target. The 5
and 3 cleavage products produced by RNase H cleavage of the 5-UTR in the presence of oligonucleotides 4 and 14 are indicated (left of
lanes 4 and 5, respectively). Synthetic target (asterisk) and targets derived from 5-UTR (bracket) are indicated (left of lanes 8 and 6, respectively).
(C) Half-ribozyme turnover rate in the presence of an equal molar amount of synthetic target (circles) or 5-UTR treated with RNase H and
oligonucleotides that flank the target (squares). Reactions were performed in the presence of 1 M half-ribozyme, 10 M SOH and pppS, and
1 nM synthetic target 1 or RNase H-cleaved 5-UTR.
changes that could be responsible for this reduced rate, are approximately the same size as the synthetic target
shown in Figure 1A (compare bracket in lane 6 to thewe note that a change at position 23 (Figure 1A) results
in the formation of a canonical Watson-Crick pair at the synthetic target in lane 8, Figure 2B). Thus, RNase H
treatment can be used to efficiently produce fragmentssite of a C/A mismatch that was a conserved feature
of all half-ribozymes produced through iterative RNA of the HCV 5-UTR from in vitro transcripts that are
approximately the same size as synthetic target 1.selection and is present in targets 1 and 3 [1].
To determine whether the RNA fragments generated
by RNase H digestion of the 5-UTR activate half-ribo-An Activator Derived from a Structured RNA
The target sequence is part of the 5-UTR of HCV, a zyme catalysis, we measured multiple turnover rates in
the presence of an equal amount of target 1 or the 5-compact RNA structure [15] that directs cap-indepen-
dent translation within cells [16]. The 5-UTR displays a UTR cleaved in the presence of oligonucleotides that
flank the target site. The observed rates are similar (7.4conserved secondary structure that forms indepen-
dently of the remaining portion of the HCV genome min1 versus 5.4 min1, respectively; Figure 2C). Thus,
not only can RNase H treatment liberate RNA fragments[15, 17]. Since the target is sequestered in an intramolec-
ular duplex within this structure, it was not surprising from the 5-UTR that resemble the synthetic target, but
most if not all of these fragments activate half-ribozymethat an in vitro transcript comprising the intact 5-UTR
did not stimulate half-ribozyme catalysis (data not catalysis to the same extent as the synthetic oligonucle-
otide species. Because the 5-UTR is likely to adopt theshown). Therefore, a strategy was devised to liberate
the RNA target from the 5-UTR such that it could acti- same structure when embedded in the viral genome
[18], these data suggest that this half-ribozyme is com-vate the half-ribozyme.
To access the target within the structured 5-UTR, it petent to detect the HCV genome derived from live virus
when integrated with an optimized method for clinicalwas treated with RNase H and DNA oligonucleotides
that are complementary to the sequences that flank the sample preparation.
target site (Figure 2A). After confirming that the UTR
remains intact in the presence of RNase H without com- Flexibility in Assay Formatting
Half-ribozyme activity can be detected directly by moni-plementary oligonucleotides (compare lane 3 with lane
2, Figure 2B), we demonstrated that addition of a single toring ligation of a radiolabeled substrate RNA on dena-
turing polyacrylamide gels ([1], Figures 1B and 2C). How-oligonucleotide complementary to sequence either 5
or 3 of the target site cleaved the 5-UTR to 100% and ever, such assays are laborious and time consuming
because they require separate steps for fractionation ofgenerated fragments of the expected sizes (lanes 4 and
5, respectively, Figure 2B). As expected, addition of both product from unreacted substrate and detection and
quantification of signal using phosphorimage analysis.oligonucleotides to RNase H reactions resulted in cleav-
age at both sites and generated a set of products that Since both substrate RNAs can be chemically modified
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Figure 3. Detection of Half-Ribozyme Activity in ELISA-like Format
(A) Assay schematic. SOH RNA was modified with a 5-fluorescein moiety (Fl-SOH, red), and a 3-biotin tag was added to pppS (pppS-Bio, blue).
The product was captured on streptavidin-coated 96-well plate and detected with an alkaline phosphatase-conjugated anti-fluorescein antibody
(yellow). The alkaline phosphatase conjugate provides secondary signal amplification by converting a modified substrate into a fluorescent
product that can be readily quantified.
(B) Kinetic performance of the fluorescein- and biotin-modified substrates. The multiple turnover ligation rates for substrate RNA combinations
are indicated: SOH/transcribed pppS (open circles), SOH/synthetic pppS (closed circles), SOH/pppS-Bio (upward triangles), Fl-SOH/transcribed
pppS (downward triangles), and Fl-SOH/pppS-Bio (squares). Assays were performed at a half-ribozyme concentration of 1 M and 0.1–10 nM
target 1. SOH and pppS were present in equimolar concentrations of 0.1–10 M (as shown) and were always 1000-fold above the target
concentration.
(C) Sensitivity of the half-ribozyme for synthetic HCV target and RNase-cleaved HCV 5-UTR in the ELISA-like format. Five replicate half-
ribozyme reactions were carried out for each amount of HCV target (0–1  108), and ligation products were quantified by ELISA-like detection
as described in Experimental Procedures. Average signal plus one standard deviation in absence of target 1 (dashed red line) or 5-UTR
(dashed blue line) are indicated. Note that the SOH and pppS sequences used in these experiments are optimized versions of those shown in
Figure 1A; the sequences of these substrate RNAs can be found in Experimental Procedures.
(labeled) during their synthesis with moieties employed ucts fractionated by gel electrophoresis is in its speed
and simplicity. The washing and buffer addition stepsin high-throughput detection assays, we set out to inte-
grate half-ribozyme-mediated signal amplification with can be accomplished by multichannel pipets or using a
robotic liquid handling station. Results from a 96-wellmore convenient assay formats.
ELISA-type assays have found application from basic ELISA-like assay can be obtained with a fluorescent
plate reader 20 min after the addition of the alkalineresearch to clinical diagnostics because the ELISA for-
mat allows for detection and quantification of analytes phosphatase substrate.
Prior to developing ELISA-like detection of half-ribo-in a nonradioactive, easy-to-use format that can be au-
tomated. ELISA assays require both capture and detec- zyme ligation product, the kinetic performance of the
half-ribozyme with the pppS-Bio and Fl-SOH substratetion steps and are usually performed in a microtiter plate.
The ability to synthesize one half-ribozyme substrate RNAs was examined using radiolabeled substrates in a
standard gel-based assay (Figure 3B). Because pppS-with a capture agent and the second substrate RNA
with a hapten for antibody detection provided a potential Bio was prepared by enzymatic ligation of a chemically
triphosphorylated oligonucleotide to a biotin-containingroute to detect half-ribozyme catalysis in an ELISA-like
format (Figure 3A). To facilitate capture of the ligation RNA, we first compared nonbiotinylated pppS prepared
in this fashion to an in vitro-transcribed pppS prepara-product, a biotin tag was introduced on the 3 end of
the 3-substrate RNA (pppS-Bio; see Experimental Pro- tion. The chemically synthesized pppS shows a minor
reduction in ligation rate relative to pppS produced by T7cedures for chemical synthesis of 5-triphosphorylated
RNAs). A fluorescein moiety, introduced at the 5 end RNA polymerase transcription (Figure 3B, open versus
closed circles). While the addition of a 3-biotin moietyof the 5 substrate RNA (Fl-SOH), allowed for detection
of the captured product. This moiety can be detected has an additional effect on the ligation rate (upward
black triangles, Figure 3B), the overall effect of exchang-directly upon ligation (data not shown) or indirectly fol-
lowing a secondary signal amplification step using an ing the transcribed pppS for a synthetic 3-biotinylated
pppS is relatively small (less than 2-fold in kmax; Figureanti-fluorescein antibody conjugated to alkaline phos-
phatase (Figure 3A). The latter protocol involves binding 3B). The introduction of a fluorescein on the 5 end of
SOH has a greater impact on the ligation rate (4-fold inthe reaction products to a streptavidin plate, washing
under denaturing and then native conditions, binding kmax). We observed that the rate reductions observed
with these modified substrates are not additive, and theand washing away excess anti-fluorescein antibody-
enzyme conjugate, and addition of an alkaline phospha- Fl-SOH performs similarly with either transcribed pppS
or chemically synthesized pppS-Bio. Thus, relative totase substrate that is converted by an enzymatic reac-
tion to a fluorescent product. The advantage of this the unmodified substrate RNAs used in a previous study,
those developed for ELISA-like formatting slightly im-system over the direct detection of radiolabeled prod-
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pede half-ribozyme catalysis, and therefore were ex- lengths of light and a change in surface color. This sys-
tem was designed to exploit the ability of the humanpected to compromise the sensitivity of target detection
when half-ribozymes were used in an ELISA-like format eye to discriminate changes in color more readily than
intensity differences. The ability to assess results visu-based on a model that predicts sensitivity of detection
from kinetic properties [1]. ally without instrumentation has enabled the production
of diagnostic assays that run in a physician’s office with-To directly investigate assay sensitivity in the ELISA-
like format, half-ribozyme ligation reactions were carried out sophisticated instrumentation. Quantification of sig-
nal using a CCD camera to generate a color differenceout with increasing amounts of synthetic HCV target or
RNase H-digested 5-UTR (n  5). The ligation product value allows assays to be run in a high-throughput mi-
croplate format. In previous studies, product detectionwas captured on a streptavidin-coated 96-well plate and
detected with an antibody coupled to alkaline phospha- by the OIA method was 5 106-fold more sensitive than
similarly formatted fluorescence detection methods us-tase. As expected based on kinetic studies with RNase
H-cleaved HCV 5-UTR (Figure 1C), the signals observed ing a CCD detection strategy [19].
We adapted this assay to detect half-ribozyme prod-in the presence of target 1 or RNase H-digested 5-
UTR were similar when signal was appreciably above uct RNA (Figure 4A). For this application, substrate RNAs
were designed such that SOH carried a 5-biotin (Bio-SOH)background. When target 1 (synthetic oligoribonucleo-
tide) was used to activate the half-ribozyme, 1  106 and the 3 end of pppS was extended by 17 nucleotides
to facilitate hybrid capture (pppS-Ext). Half-ribozymetarget molecules (1.6 attomol, 330 fM) produced a signal
distinct from that in the absence of target by one stan- product RNA is captured by an immobilized antisense
oligonucleotide, and the 5-biotin label is detected usingdard deviation (red circles, Figure 3C). At lower amounts
of target, signal reached a plateau at the level observed a peroxidase-avidin conjugate. To avoid detection of
unligated Bio-SOH annealed to pppS-Ext, a competitorin the absence of target. Similarly, RNase H-digested
5-UTR provided a signal above background at 3  106 oligonucleotide that binds to the entire portion of pppS-
Ext that does not interact with the capture oligonucleo-target molecules (5 attomol, 1 pM) (blue squares, Figure
3C). The ability of the half-ribozyme to equally detect tide was used to abrogate its ability to form base pairs
with Bio-SOH (Figure 4A).3  106 copies of a synthetic target oligonucleotide or
a sequence derived from the intact HCV 5-UTR repre- Kinetic characterization of the Bio-SOH/pppS-Ext sub-
strate pair in analogy to the analysis of the substratesents at least a 6000-fold improvement in sensitivity
relative to the next most sensitive ribozyme-based de- RNAs used in the ELISA-like assay indicated that Bio-
SOH and pppS-Ext reduce maximal half-ribozyme ratetection strategy, which required RT-PCR amplification
for detection of an unstructured DNA [6]. by roughly 4-fold relative to the originally reported sub-
strate RNAs (data not shown). The rate reduction relativeAs predicted from earlier studies that established the
sensitivity of the HCV-activated half-ribozyme using ra- to the unmodified RNAs is similar to that observed with
substrate RNAs used in ELISA-like assays. In this case,diolabeled substrate RNAs [1], the sensitivity of the
ELISA-like assay is dictated in part by the target-inde- however, the kinetic defect was primarily attributed to
the 3 substrate RNA (pppS-Ext) rather than the 5 sub-pendent ligation reaction (i.e., the signal observed in the
absence of target). In the ELISA-formatted assay, this strate RNA (Bio-SOH).
As predicted from the kinetic equivalence of half-ribo-target-independent reaction produces a signal equiva-
lent to that observed in the presence of approximately zyme catalysis using substrate RNAs formatted for the
OIA and ELISA-like assays, the sensitivity of detection1  105 target molecules (Figure 3C); this background
signal is approximately 10-fold higher than the signal of the synthetic oligoribonucleotide target (target 1) in
OIA-formatted half-ribozyme reactions is similar to thatobserved when the substrate RNAs are added to the
streptavidin plate without prior incubation either in the observed in ELISA-formatted reactions (compare Figure
3C to Figures 4B and 4C). In both assays, signal sepa-presence or the absence of half-ribozyme (80–200 RFU;
data not shown). We previously demonstrated that the rated from background by one standard deviation is
evident at 1  106 target molecules (1.6 attomol, 330background reaction is not catalyzed by the half-ribo-
zyme, but rather represents the intrinsic reactivity of the fM) and reached a plateau at lower amounts of target
1. In the OIA assay, a transition between the backgroundSOH/pppS substrate complex [1].
gold color and positive blue is observed at this target
level (Figure 4B). In the quantified data, the signal from
Detection on Optical Surfaces 1  106 target molecules is clearly above the average
Optical immunoassays (OIA) have previously been used background signal observed in reactions containing 0
to detect nucleic acid targets [19, 20]. Existing OIA to 1  105 target molecules (Figure 4C). As with the
assays use an immobilized antisense probe to capture ELISA-like format, half-ribozyme-mediated detection is
a target nucleic acid on the surface of a silicon wafer. at least 6000-fold greater than the maximal reported
A second antisense probe carrying biotin interacts with sensitivity of other nucleic acid-activated ribozymes [6].
a different sequence in the target, and the biotin moiety
is then detected using a horseradish peroxidase-avidin
conjugate that converts a soluble substrate into an insol- Sensitivity of Detection
The sensitivity of detection provided by ELISA-like anduble product. Local deposition of the product on the
atomically flat silicon wafer changes the optical thick- OIA-formatted half-ribozyme reactions is similar to the
sensitivity of protein detection provided by standardness of the surface. The change in optical thickness
results in destructive interference at certain wave- immunoassays. Immunological assays for protein de-
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Figure 4. Detection of Half-Ribozyme Activity on Optically Coated Silicon Wafers
(A) The optical immunoassay format employs an extended pppS (blue) that is captured by a hybridization probe (black) immobilized on the
surface of the silicon wafer (gold). The SOH RNA (red) carries a 5-biotin moiety, which allows captured half-ribozyme ligation product to bind
a steptavidin-horseradish peroxidase conjugate (SA-HRP) that converts a soluble substrate (TMB) into an insoluble product. Localized
precipitation of the product leads to the deposition of a thin film on the suface of the wafer, which alters the optical thickness of the surface
and changes the color of the wafer. To eliminate background caused by the annealing of unligated Bio-SOH to the to the captured pppS-Ext,
a DNA oligonucleotide (tan) was added to compete for binding to the complementary sequence.
(B) Visual detection of half-ribozyme product RNA using the optical immunoassay format. Half-ribozyme reactions were carried out with
increasing amounts of HCV target (0–1  108), and the products were detected on silicon wafers as described in Experimental Procedures.
In the absence of product deposition, the plate is gold. Localized product precipitation shifts the color of the plate to a purple/blue hue that
is apparent at  1  106 target molecules. As the thickness on the surface increases with increasing amounts of ligation product detected,
surface color transitions from gold to purple, from purple to blue, and then from blue to white. As surface thickness increases even further,
the color will transition back from white to blue due to the periodic nature of light. Consequently, signal at 1  108 target molecules appears
lower than signal at 1  107 target molecules.
(C) Quantification of data from panel B was performed using a CCD camera and plotted as a function of HCV target amount (see Experimental
Procedures). Average signal plus one standard deviation in absence of target 1 (dashed red line) is indicated.
tection have a calculated theoretical maximum limit of be possible. The sensitivity of detection of the synthetic
target oligonucleotide by half-ribozymes in the assaysdetection of 20 fM to 0.2 fM based on typical antibodies
with affinities of 109 M to 1011 M, respectively [21]. In reported here is diminished approximately 140-fold rela-
tive to that reported in an assay that directly monitoredpractice, however, highly sensitive standard immunoas-
says have limits of detection of 35 to 700 fM [22, 23]. radiolabeled product RNA (1 106 molecules, Figures
3C and 4C, versus 7000 molecules, [1]). The differingBy comparison, half-ribozymes display a sensitivity of
detection in both ELISA-like and OIA-like assays of330 sensitivity in ELISA-like and OIA formats is largely a
consequence of how sensitivity is defined here (separa-fM (1  106 molecules) of an unstructured HCV target
RNA or (Figures 3C and 4C) or1 pM (3 106 molecules) tion of target signal and control signal by one standard
deviation) relative to the prior study (intersection of re-of the 5-UTR of HCV (Figure 3C).
Even though half-ribozymes are currently comparable gressed signal as a function of target concentration with
signal value in absence of target). The large CV observedto immunoassays in sensitivity, greater sensitivity may
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in the absence of target and in the presence of low levels zymes can detect natural HCV sequence variants, (2)
a half-ribozyme can detect its target when derivedof target in both ELISA-like and OIA assays (51% and
31%, respectively, in the absence of target) results in a from a structured RNA, and (3) half-ribozyme-based
signal amplification can be integrated with two immu-higher limit of detection in these assays. These high CVs
are not intrinsic to half-ribozyme catalysis, since the noassay detection platforms. Although the sensitivity
of detection afforded by ELISA and OIA formats re-coefficient of variance (CV) is less than 8% in assays
that monitor radiolabeled product RNA directly [1]. mains to be optimized, the sensitivity in the assays
reported here is equivalent to that provided by immu-Therefore, efforts to minimize data scatter through fur-
ther assay development could dramatically improve nological methods currently used as primary screens
for viral contamination of blood products. Together,sensitivity in both ELISA-like and OIA formats.
Following a model that predicts the sensitivity af- these properties suggest that ribozyme-based re-
agents like the one described here may prove usefulforded by half-ribozymes from the ratio of target-acti-
vated catalysis and background ligation [1], we attribute for viral screening and for other diagnostic applica-
tions.a smaller part of the reduced sensitivity of the ELISA-like
and OIA-formatted assays to the diminished catalytic
Experimental Proceduresperformance of the half-ribozyme when utilizing modi-
fied substrate RNAs (Figure 3B and data not shown).
RNA Sequences and Preparation
Consequently, optimization of the utilization of the modi- The SOH RNAs and synthetic HCV target RNAs shown in Figure
fied substrate RNAs by the half-ribozyme should im- 1A and the “noncognate” RNA used in Figure 1B (5-ACACCGGAA
UUGCCAGGACGACCGGGUCCUUUCUUGGAUAA) were producedprove sensitivity in either assay format. This improve-
through standard oligoribonucleotide synthesis procedures. Non-ment in utilization could be realized either by “training”
biotinylated pppS RNAs were prepared by T7 RNA polymerase tran-half-ribozymes to use modified substrate RNAs through
scription; pppS carrying a 3-biotin was made by chemical modifica-iterative RNA selection or by screening substrate RNAs
tion of synthetically produced oligonucleotides as described below.
for positions where modifications are best tolerated. The half-ribozyme shown in Figure 1A was used in all experiments
Through a combination of assay and half-ribozyme per- and was produced by T7 RNA polymerase transcription using a
template produced by PCR amplification of a cloned ribozyme se-formance improvements, further gains in the sensitivity
quence [1] with appropriate primer sequences. The HCV 5-UTRafforded by half-ribozymes in immunodiagnostic assays
(nt 1–397) was produced by run-off transcription of a restrictioncan be expected.
endonuclease-digested plasmid template carrying a portion of theCurrent screening for HCV infection is performed
HCV genome under the control of a T7 promoter. Substrate RNAs
through the detection of anti-HCV antibodies [24, 25]. used in ELISA-like and OIA-like assays were modified versions of
However, this approach cannot distinguish individuals the sequences shown in Figure 1A. The sequences of these sub-
strates are as follows: Fl-SOH (5 fluorescein-AAACCAGUG), pppS-who are actively infected from those who have cleared
Bio (GGAAGUCUAAACCACUGGUACAA-biotin), Bio-SOH (5 biotin-the virus and reports recently infected individuals who
AAACCAGUG), and pppS-Ext (5-GGAAGUCUAAACCACUGGUAhave yet to seroconvert as HCV negative [24, 25]. To
CAAGCGUAACUCUGUCGAUCG).address these deficits, detection of HCV antigens has
Synthetic pppS RNAs were produced by splint-directed ligation
been added to screening procedures, but the hypervari- of the chemically triphosphorylated sequence pppGGAAGU to the
ability of viral proteins limits the ultimate effectiveness remaining portion of pppS using T4 DNA ligase [30]. The 5-triphos-
phorylated oligonucleotide was prepared by subjecting a solid sup-of this approach [24]. Nucleic acid-based detection
port-bound oligonucleotide to a modified procedure used for themethods, such as polymerase chain reaction (PCR) and
preparation of nucleoside 5-triphosphate [31] as described below.transcription mediated amplification (TMA), have dem-
The oligonucleotide (GGAAGU) was synthesized on controlledonstrated a superior solution to these challenges be-
pore glass (CPG) beads on a 100 mole scale using standard phos-
cause they detect only active infections, can be directed phoramidite chemistry. Approximately one-half of this synthesis was
to the most highly conserved portions of the HCV ge- dried under vacuum in a synthesis column for 2 hr at 35C. The
column was washed with 20 ml dry pyridine followed by 20 ml drynome, and offer greater sensitivity than immunological
DMF and 10 ml dioxane-pyridine-DMF (6:3:1). A freshly preparedmethods [25]. However, the high cost of these methods
solution of salicyl chlorophosphite (2.03 g) in dioxane (8 ml) washas limited their application in blood screening [26]. The
slowly pushed through the column over the course of 20 min. Thehalf-ribozyme system that we report here has a current
column was then washed with 20 ml dioxane followed by 20 ml
sensitivity of detection similar to immunological meth- acetonitrile. A well-mixed solution of 0.5 M P2O74·1.5 Bu3N (2.28 g,
ods used to detect viral contamination of blood prod- Sigma-Aldrich, Inc.) in 9 ml DMF-Bu3N (6.2:1) was then slowly
pushed through the column for 20 min. The column was then washeducts, but offers the other benefits of nucleic acid-testing
with 20 ml dry DMF followed by 20 ml acetonitrile. Ten milliliters ofmethods while retaining the high throughput and lower
oxidation solution (3g I2 in H2O-pyridine-THF 2:20:75 v/v) was pushedcost of immunoassays.
through the column for 30 min. The column was washed with 20 ml
70% pyridine-water, 20 ml acetonitrile, 20 ml THF, and dried under
high vacuum at 35C.
Significance The CPG beads were removed from the column and treated with
10 ml of methylamine for 5 hr at 35C. Solvents were then evaporated
under vacuum. The resin was treated for 16 hr with 2 ml of 1 MSeveral authors have discussed the potential use of
TBAF (Sigma-Aldrich, Inc.). Prior to use, TBAF was dried for 3 daystarget-activated ribozymes in clinical diagnostic appli-
over activated 4A molecular sieves. The TBAF was quenched withcations [27–29], and we previously developed a ribo-
5 ml of 1.5 M sodium acetate (pH 5.2). THF was removed underzyme system capable of detecting low-abundance nu-
vacuum, and the aqueous layer was extracted twice with ethyl ace-
cleic acids [1]. The current work supports the prospect tate. The product pppRNA was precipitated with 20 ml of ethanol,
of using ribozyme-based systems to monitor viral nu- centrifuged at 16000 g, and purified via denaturing gel electropho-
resis.cleic acids by demonstrating that (1) the half-ribo-
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Kinetic Assays plus 0.1% Tween-20, and 100 l of AttoPhos substrate (Boehringer
Mannheim, Inc.) was applied. Following a 20 min reaction at roomThe half-ribozyme kinetic assays were performed at 23C in 30 mM
Tris-HCl (pH 7.5), 160 mM MgCl2, 700 mM KCl, and 0.6 mM EDTA. temperature, the results were quantified on an Applied Biosystems
Cytofluor series 4000 fluorimager.Half-ribozyme and substrate RNA concentrations used in each
assay are provided in the appropriate figure legends. For gel-based
kinetic assays (Figures 1B, 2C, and 3B), a trace amount of added
OIA Detectionsubstrate was radiolabeled. Either SOH was radiolabeled using T4
Surface Preparationpolynucleotide kinase, or pppS was transcribed in the presence of
Details of the preparation of the optically coated silicon wafers were-[32P]-GTP. Prior to each reaction, the half-ribozyme and target
described previously (18). Briefly, Si3N4 was applied to crystallinewere refolded by heating at 80C for 2 min., adding concentrated
silicon wafers in a vapor deposition chamber. The polymer, T-struc-reaction buffer, and allowing the mixture to cool to 23C over 5 min.
ture aminoalkyl poly-dimethyl siloxane (TSPS; United ChemicalReactions were initiated by addition of substrate RNAs, and aliquots
Technologies) was applied using a spin coater and cured at 150C forwere quenched into formamide gel-loading dye containing 50 mM
24 hr to create a thin film biosensor surface. An amino-functionalizedEDTA at the appropriate times. Products were resolved on 15%
surface (TSPS/PPL) was prepared by passively adsorbing 5 g/mldenaturing polyacrylamide gels. Observed turnover rates were
of poly (lys-phe) (Sigma, St. Louis, MO) in 1 PBS, 2M NaCl (pH 6)calculated from the initial phase of the reaction (	20% substrate
overnight at room temperature. The TSPS/PPL wafer was diced intoconverted to ligated product) and fit to kobs [ligated product]/([tar-
49 mm2 chips using a scribe/break robot as described else-get-half-ribozyme]*time). Michaelis-Menten parameters were estab-
where [18].lished by varying concentration of half-ribozyme in the presence of
Probe Immobilizationtrace target, and the data were fit to v  [E*][E]kmax/(Kapp
[E]), where
Oligonucleotides were synthesized with a 5 amino modifier C6v equals rate at each [E], [E*] represents the concentration of active
phosphoramidite (Glen Research), resuspended in water, and storedhalf-ribozyme (defined as the concentration of target), Kapp is the
at –70C until further use. The capture probe (5-XYCGATCGACAhalf-ribozyme concentration required for half-maximal activation,
GAGTTACGCTTGT-3, where X  C6 amine amidite and Y  C18and kmax equals the maximal catalytic rate. For assays in which the
spacer amidite) was dried and resuspended in 5 l of 0.1M TEAAconcentration of active half-ribozyme ([E*], defined by the limiting
(pH 7.8). Disuccinimidyl suberate (Pierce) was dissolved to 28 mg/mltarget concentration) was fixed and the concentration of RNA sub-
in dimethyl formamide (Aldrich), and 22 l was added to the capturestrate complex varied (e.g., Figure 3B), the substrate concentration
probe and incubated at room temperature for 10 min. Ice-cold water([S]) replaces [E] in the equation above, and Kapp is the substrate
was added (200 l), followed by three extractions with 600 l ofconcentration required for half-maximal activation.
ethyl acetate (Aldrich). Ice-cold water was added (200 l), and the
sample was extracted twice with 400l of iso-butyl alcohol (Aldrich).RNase H Digestions
Probes were resuspended to 500 l in ice-cold water and placedReactions for the oligonucleotide-directed RNase digestion of HCV
on ice. The probe was resuspended to 150 nM in 0.1 M phosphate5-UTR (nt 1–397) were carried out in a 5 l reaction containing
buffer (pH 7.8), and 15 l was applied to each chip. The probe spot20 mM Tris (pH 7.5), 100 mM KCl, 10 mM MgCl2, 0.1 mM DTT, 0.5
was incubated in a humid environment for 2 hr. The chip surfaceunits RNase H (Roche), 1 M DNA oligonucleotide, and varying
was washed thoroughly with water and then “stripped” of passivelyconcentrations of target RNA. To assist in the annealing of the DNA
adsorbed material with 0.1% SDS at 53C for 2 hr. The chip wasoligonucleotides, the RNA target and targeting DNAs were heated
then washed again with water, dried under a nitrogen stream, andat 95C for 5 min in Tris and KCl and allowed to cool to room
stored in a N2 box until further use.temperature prior to the addition of the remaining buffer compo-
Assay Protocolnents and RNase H. Reactions were performed at 37C for 30 min.
Sensitivity determinations (n 4) were carried out at 23C in 30 mMThe products were ethanol precipitated, washed with 70% ethanol,
MES (pH 6.0), 0.7 M KCl, 160 mM MgCl2, 1 M half-ribozyme, 1 Mresuspended in 2.5 l of water, and used directly in half-ribozyme
Bio-SOH, and 1 M pppS-Ext. The HCV target was present at 0 orligation reactions.
1  104–1  108 molecules per reaction. Half-ribozyme products
(5 l) were mixed with 5 l of 7 mM competitor (5-ACC AGT GGT
ELISA-like Detection
TTA GAC TTC C-3) and diluted with 45 l hybridization solution
Sensitivity determinations (n 5) were carried out at 23C in 30 mM
(5 SSC, 0.1% SDS, 0.5% BlockAid [Thermo Electron, Louisville,
MES (pH 6.0), 0.7 M KCl, 160 mM MgCl2, 0.6 mM EDTA, 1 M half- CO]). Following 2 min of heating at 70C, samples (50l) were loaded
ribozyme, 1 M Fl-SOH, and 1 M pppS-Bio. The HCV target, either on OIA chips. Hybridization was performed at room temperature for
synthetic target or RNase H-cleaved 5-UTR, was present at 0 or
30 min. Plates were then washed with wash buffer A (0.1% SDS/0.1
1  103–1  108 molecules per reaction. The final reaction volume
SSC) followed by wash buffer B (0.1 SSC). A conjugate solution,
was 5l. Target stocks at appropriate concentrations were prepared
peroxidase-conjugated IgG fraction monoclonal mouse anti-biotin
by serial dilution of a concentrated stock into 100 ng/l yeast tRNA.
(Jackson Research), of 1 g/ml (made in hybridization buffer) was
The diluted HCV-UTR was treated with RNase H, ethanol precipi-
added to each well (125 l), and samples were incubated at room
tated, and redissolved in water as described above. An individual
temperature for 10 min, followed by washing with wash buffer A,
RNase H reaction was performed for each half-ribozyme assay, and
then by buffer B. TMB reagent (BioFX) was added (150 l), and
the concentration of RNase H-cleaved HCV-UTR in each assay is
plates were incubated for 10 min at room temperature, then washed
the amount of target in the initial RNase H reaction. Reactions were
with ddH2O. Chips were finally washed with methanol manually andassembled as described for the kinetic assays above and run for
dried upside down in a 65C oven.
19 hr. The reaction was then diluted in 100 l binding buffer (PBS:
CCD Camera Quantitation
20 mM phosphate [pH 7.5], 150 mM NaCl) and transferred to a 96-
Individual chips were imaged using a SSC-DC54 CCD camera (Sony)
well steptavidin-coated microtiter plate (Amersham Pharmacia, Inc.)
with an illuminator (Dolan-Jenner Industries, Inc., Lawrence, MA).
that had been prewashed with 3 200 l Tris-buffered saline (TBS:
Images were quantified using Wit image processing software (Cor-
25 mM Tris-HCl [pH 7.2], 150 mM NaCl). The plate was covered and
eco Inc., Quebec, Canada). The color change of the surface was
incubated on a shaker for 1 hr. The product was removed, and the
quantified using a color difference relation as follows:
plate was washed with 3 200 l of TBS plus 7 M urea, then 3
200 l TBS plus 0.1% Tween-20. Note that background associated
with the annealing of unligated Fl-SOH to the immobilized pppS-Bio CD 
((Rs  Rb)2 
 (Gs  Gb)2 
 (Bs  Bb)2)1/2
(Rb 
 Gb 
 Bb)/3.substrate through Watson-Crick base pairing was reduced/elimi-
nated via the denaturing washes. One hundred microliters of an
alkaline phosphatase-conjugated anti-FITC antibody (Boehringer The surface was divided into two areas, the background and the
capture probe spot. The background was defined as the entire sur-Mannheim, Inc.) diluted 1:5000 in SuperBlock Buffer (Pierce) was
added, and the reaction was incubated for 30 min on a shaker. face, whereas the capture probe spot was the area encompassing
the capture probe. The software calculated the average readingsUnbound conjugate was removed by washing with 3 200 l TBS
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